Egyszerű nézet

dc.contributor.author Csiszar, Anna
dc.contributor.author Tarantini, Stefano
dc.contributor.author Yabluchanskiy, Andriy
dc.contributor.author Balasubramanian, Priya
dc.contributor.author Kiss, Tamás
dc.contributor.author Farkas, Eszter
dc.contributor.author Baur, Joseph A
dc.contributor.author Ungvári, Zoltán István
dc.date.accessioned 2021-06-21T06:47:02Z
dc.date.available 2021-06-21T06:47:02Z
dc.date.issued 2019
dc.identifier 85064468074
dc.identifier.citation journalVolume=316;journalIssueNumber=6;journalTitle=AMERICAN JOURNAL OF PHYSIOLOGY: HEART AND CIRCULATORY PHYSIOLOGY;pagerange=H1253-H1266;journalAbbreviatedTitle=AM J PHYSIOL HEART C;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/7939
dc.identifier.uri doi:10.1152/ajpheart.00039.2019
dc.description.abstract Age-related alterations in endothelium and the resulting vascular dysfunction critically contribute to a range of pathological conditions associated with old age. To rationally develop therapies that improve vascular health and thereby increase health span and lifespan in older adults, it will be essential to understand the cellular and molecular mechanisms contributing to vascular aging. Pre-clinical studies in model organisms demonstrate that NAD+ availability decreases with age in multiple tissues and that supplemental NAD+ precursors can ameliorate many age-related cellular impairments. Here we provide a comprehensive overview of NAD+ dependent pathways (including the NAD+ utilizing sirtuins and poly (ADP-ribose) polymerase enzymes) and the potential consequences of endothelial NAD+ deficiency in vascular aging. The multifaceted vasoprotective effects of treatments that reverse the age-related decline in cellular NAD+ levels are discussed. The preventive and therapeutic potential of NAD+ intermediates as effective, clinically relevant interventions in older adults at risk for ischemic heart disease, vascular cognitive impairment and other common geriatric conditions and diseases that involve vascular pathologies (e.g. sarcopenia, frailty) is critically discussed. We propose that NAD+ precursors (e.g., nicotinamide riboside, nicotinamide mononucleotide, niacin) should be considered as a critical component of combination therapies to slow the vascular aging process and increase cardiovascular health span.
dc.format.extent H1253-H1266
dc.relation.ispartof urn:issn:0363-6135
dc.title Role of endothelial NAD+ deficiency in age-related vascular dysfunction
dc.type Journal Article
dc.date.updated 2019-10-29T09:12:00Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 30611531
dc.identifier.wos 000470719600002
dc.identifier.pubmed 30875255
dc.contributor.department SE/AOK/K/Pulmonológiai Klinika
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet